Correcting mitochondrial dynamics, metabolic control of pathogenic or therapeutic cells emerge among translational innovations in BioCentury’s survey of 2023 publications
With $100M in series A funding, ‘2.0’ gene therapy company aims to treat retinitis pigmentosa using a channelrhodopsin variant designed for greater light sensitivity